News and Trends 11 Jun 2020 AbbVie and Genmab Strike €3.4B Immuno-Oncology Megadeal …sales milestones. The two companies will jointly develop and commercialize three of Genmab’s anti-cancer antibody drugs, which are currently in phase I trials. Genmab’s antibody drugs — which are able… June 11, 2020 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2019 Innate Pharma Raises €62M IPO to Develop Antibody Drugs for Cancer The French company Innate Pharma has raised a Nasdaq IPO of €62.1M ($68.8M) to fund the development of antibody immunotherapies for solid tumors and blood cancer. Innate Pharma’s lead candidate… October 17, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 18 May 2017 Abcam Makes Final Payment in the Acquisition of an US Antibody Biotech Abcam has paid US-based AxioMx a final €4.5M milestone based on performance, completing an acquisition that totals €36.4M. Giant antibody maker Abcam, founded by star biotech entrepreneur Jonathan Milner and… May 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Apr 2025 Top biotech deals of March 2025 …was approved by the U.S. Food and Drug Administration (FDA) to treat multiple myeloma in 2021. Meanwhile, French pharmaceutical company Sanofi has acquired California-based antibody developer Dren Bio’s bispecific myeloid… April 2, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 29 Mar 2017 Get Ready for One of the Biggest New Drug Approvals of the Year …such as those implicated in atopic dermatitis, asthma and allergies. The antibody represents the first drug targeting the IL-4/IL-13 pathways. The antibody is indicated for the treatment of moderate to… March 29, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Jun 2023 Five biotech companies making a name for themselves in Vancouver …antibody therapy treatment for COVID-19, when, in 2021, bamlanivimab, used together with etesevimab, became the first monoclonal antibody medicine for COVID-19 to receive U.S. Food and Drug Administration (FDA) Emergency… June 30, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2023 Alchemab Therapeutics unveils Alzheimer’s candidate Alchemab Therapeutics, an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, has unveiled data on ATLX-1088, its newly-discovered preclinical Alzheimer’s candidate, at the Antibody Industrial Symposium… June 22, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2018 Innate’s Cancer Immunotherapy Combo Beats Standard Treatment Twofold …cancer patients that is very hard to treat. A checkpoint inhibitor antibody In the Phase II trial, Innate’s checkpoint inhibitor antibody was part of a combination therapy. While… October 22, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jun 2017 What Cancer Therapies did European Biotechs Showcase at ASCO 2017? …competitors, BMS, MSD and Roche, in the coveted PD-L1 / PD-1 checkpoint inhibitor space. The Danish antibody giant Genmab presented a Phase I/IIa update on HuMax-AXL-ADC, an antibody-drug conjugate (ADC)… June 7, 2017 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2017 Samsung Bioepis Gets European Approval for Biosimilar of Best-Selling Antibody …anti-TNF-α antibody launched by Samsung Bioepis, making it the first company with biosimilars of all blockbusters that that target TNF-α. The other two are Benepali, a biosimilar of Amgen and… August 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 11 Jan 2024 Ten NK cell therapy companies to look out for this year …therapy that is designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of monoclonal antibodies. This way, the drug can kill auto-antibody producing B cells. The candidate is also being… January 11, 2024 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 31 Jan 2017 Biologicals on the Brain: Biotech in Neurodegenerative Disease …long anticipated Alzheimer’s antibody, failed in their third attempt at a late stage trial last year, it crushed patients’ hopes and raised doubts about whether or not targeting amyloid-beta plaques,… January 31, 2017 - 7 minutesmins - By Diana Kwon Share WhatsApp Twitter Linkedin Email